Journal of Microbiology and Biotechnology

The Korean Society for Microbiology and Biotechnology (한국미생물·생명공학회)
권호 표지
DOI QR코드

DOI QR Code

The Probiotic Effects of the Saccharomyces cerevisiae 28-7 Strain Isolated from Nuruk in a DSS-Induced Colitis Mouse Model

  • Lee, Jang Eun (Reserch Group of Traditional Food, Korea Food Research Institute) ;
  • Lee, Eunjung (Reserch Group of Traditional Food, Korea Food Research Institute)
  • Received : 2022.06.17
  • Accepted : 2022.06.27
  • Published : 2022.07.28
Download PDF
⟨ Previous Next ⟩

Abstract

Probiotics are microorganisms that can benefit host health when ingested in a live state, and lactic acid bacteria are the most common type. Among fungi, Saccharomyces boulardii (SB) is the only strain known to have a probiotic function with beneficial effects on colitis; however, information on other probiotic yeast strains is limited. Therefore, this study aimed to discover yeast strains expressing intestinal anti-inflammatory activities by exhibiting probiotic properties in dextran sodium sulfate (DSS)-induced colitis mice model. Nuruk (Korean traditional fermentation starter) containing various microbial strains was used as a source for yeast strains, and S. cerevisiae 28-7 (SC28-7) strain was selected with in vitro and in vivo characteristics to enable survival in the intestines. After 14 days of pretreatment with the yeast strains, DSS was co-administered for six days to induce colitis in mice. The results revealed that the disease activity index score was lowered by SC28-7 treatment compared to the DSS group, and the colon length and weight/length ratio were recovered in a pattern similar to that of the normal group. SC28-7 administration significantly reduced the secretion of pro-inflammatory cytokines in the serum and modified the mRNA expression of inflammatory cytokines (interleukin-1β, transforming growth factor-β, and interferon-γ) and proteins involved in gut barrier functions (mucin 2, mucin 3, zonula occludens-1, and occludin) in colon tissues. These results indicate that SC28-7 attenuates DSS-induced colon damage and inflammation, supporting its future use as a probiotic yeast for treating and preventing intestinal inflammatory diseases such as inflammatory bowel disease.

Keywords

Acknowledgement

This project was supported by Main Research Program (E0201100-03) of the Korea Food Research Institute (KFRI) funded by the Ministry of Science and ICT.

References

  1. Ranjha M, Shafique B, Batool M, Kowalczewski PL, Shehzad Q, Usman M, et al. 2021. Nutritional and health potential of probiotics: a review. Appl. Sci. 11: 11024.
  2. Goktas H, Dertli E, Sagdic O. 2021. Comparison of functional characteristics of distinct Saccharomyces boulardii strains isolated from commercial food supplements. Lwt-Food Sci. Technol. 136: 110340.
  3. Lara-Hidalgo C, Hernandez-Sanchez H, Hernandez-Rodriguez C, Dorantes-Alvarez, Lago HD. 2017. Yeasts in fermented foods and their probiotic potential. Austin. J. Nutr. Metab. 4: 1-8.
  4. Lazo-Velez MA, Serna-Saldivar SO, Rosales-Medina MF, Tinoco-Alvear M, Briones-Garcia M. 2018. Application of Saccharomyces cerevisiae var. boulardii in food processing: a review. J. Appl. Microbiol. 125: 943-951. https://doi.org/10.1111/jam.14037
  5. Consoli MLD, da Silva RS, Nicoli JR, Bruna-Romero O, da Silva RG, Generoso SD, et al. 2016. Randomized clinical trial: impact of oral administration of Saccharomyces boulardii on gene expression of intestinal cytokines in patients undergoing colon resection. JPN J. Parenter. Enteral Nutr. 40: 1114-1121. https://doi.org/10.1177/0148607115584387
  6. Stier H, Bischoff SC. 2016. Influence of Saccharomyces boulardii CNCM I-745 on the gut-associated immune system. Clin. Exp. Gastroenterol. 9: 269-279. https://doi.org/10.2147/CEG.S111003
  7. Zhou BG, Chen LX, Li B, Wan LY, Ai YW. 2019. Saccharomyces boulardii as an adjuvant therapy for Helicobacter pylori eradication: a systematic review and meta-analysis with trial sequential analysis. Helicobacter 24: e12651.
  8. Lee JE, Ha JS, Park HY, Lee E. 2020. Alteration of gut microbiota composition by short-term low-dose alcohol intake is restored by fermented rice liquor in mice. Food Res. Int. 128: 108800.
  9. Lee E, Kim J-H, Lee J-E. 2021. Research on the probiotic yeast Saccharomyces cerevisiae var. Boulardii-03 derived from traditional nuruk. J. Korean Soc. Food Sci. Nutr. 50: 1392-1398. https://doi.org/10.3746/jkfn.2021.50.12.1392
  10. Lee JE, Lee AR, Kim H, Lee E, Kim TW, Shin WC, et al. 2017. Restoration of traditional Korean nuruk and analysis of the brewing characteristics. J. Microbiol. Biotechnol. 27: 896-908. https://doi.org/10.4014/jmb.1610.10039
  11. Gommeaux J, Cano C, Garcia S, Gironella M, Pietri S, Culcasi M, et al. 2007. Colitis and colitis-associated cancer are exacerbated in mice deficient for tumor protein 53-induced nuclear protein 1. Mol. Cell Biol. 27: 2215-2228. https://doi.org/10.1128/MCB.01454-06
  12. Everard A, Matamoros S, Geurts L, Delzenne NM, Cani PD. 2014. Saccharomyces boulardii administration changes gut microbiota and reduces hepatic steatosis, low-grade inflammation, and fat mass in obese and type 2 diabetic db/db mice. mBio 5: e01011-01014.
  13. Liu JJ, Zhang GC, Kong, II, Yun EJ, Zheng JQ, Kweon DH, et al. 2018. A mutation in PGM2 causing inefficient galactose metabolism in the probiotic yeast Saccharomyces boulardii. Appl. Environ. Microbiol. 84: e02858-17.
  14. Mitterdorfer G, Kniefel W, Viernstein H. 2001. Utilization of prebiotic carbohydrates by yeasts of therapeutic relevance. Lett. Appl. Microbiol. 33: 251-255. https://doi.org/10.1046/j.1472-765X.2001.00991.x
  15. Edwards-Ingram L, Gitsham P, Burton N, Warhurst G, Clarke I, Hoyle D, et al. 2007. Genotypic and physiological characterization of Saccharomyces boulardii, the probiotic strain of Saccharomyces cerevisiaev. Appl. Environmen. Microbiol. 73: 2458-2467. https://doi.org/10.1128/AEM.02201-06
  16. Graff S, Chaumeil JC, Boy P, Lai-Kuen R, Charrueau C. 2008. Influence of pH conditions on the viability of Saccharomyces boulardii yeast. J. Gen. Appl. Microbiol. 54: 221-227. https://doi.org/10.2323/jgam.54.221
  17. Graff S, Chaumeil JC, Boy P, Lai-Kuen R, Charrueau C. 2008. Influence of pH conditions on the viability of Saccharomyces boulardii yeast. J. Gen. Appl. Microbiol. 54: 221-227. https://doi.org/10.2323/jgam.54.221
  18. Khatri I, Tomar R, Ganesan K, Prasad GS, Subramanian S. 2017. Complete genome sequence and comparative genomics of the probiotic yeast Saccharomyces boulardii. Sci. Rep. 7: 371.
  19. Arafa HM, Hemeida RA, El-Bahrawy AI, Hamada FM. 2009. Prophylactic role of curcumin in dextran sulfate sodium (DSS)-induced ulcerative colitis murine model. Food Chem. Toxicol. 47: 1311-1317. https://doi.org/10.1016/j.fct.2009.03.003
  20. Rodriguez-Nogales A, Algieri F, Garrido-Mesa J, Vezza T, Utrilla MP, Chueca N, et al. 2018. Intestinal anti-inflammatory effect of the probiotic Saccharomyces boulardii in DSS-induced colitis in mice: Impact on microRNAs expression and gut microbiota composition. J. Nutr. Biochem. 61: 129-139. https://doi.org/10.1016/j.jnutbio.2018.08.005
  21. Qi XW, Xia SH, Yin Y, Jin LF, Pu Y, Hua D, et al. 2014. Expression features of CXCR5 and its ligand, CXCL13 associated with poor prognosis of advanced colorectal cancer. Eur. Rev. Med. Pharmacol. Sci. 18: 1916-1924.
  22. Zhu ZY, Zhang XK, Guo HL, Fu L, Pan GL, Sun YG. 2015. CXCL13-CXCR5 axis promotes the growth and invasion of colon cancer cells via PI3K/AKT pathway. Mol. Cell Biochem. 400: 287-295. https://doi.org/10.1007/s11010-014-2285-y
  23. Cremonesi E, Governa V, Garzon JFG, Mele V, Amicarella F, Muraro MG, et al. 2018. Gut microbiota modulate T cell trafficking into human colorectal cancer. Gut 67: 1984-1994. https://doi.org/10.1136/gutjnl-2016-313498
  24. Zhao Q, Guo J, Wang G, Bi Y, Cheng X, Liao Y, et al. 2021. CXCL13 promotes intestinal tumorigenesis through the activation of epithelial AKT signaling. Cancer Lett. 511: 1-14. https://doi.org/10.1016/j.canlet.2021.04.012
  25. Alzoghaibi MA, Al-Mofleh IA, Al-Jebreen AM. 2008. Neutrophil chemokines GCP-2 and GRO-alpha in patients with inflammatory bowel disease. J. Digest Dis. 9: 144-148. https://doi.org/10.1111/j.1751-2980.2008.00336.x
  26. Morris KT, Castillo EF, Ray AL, Weston LL, Nofchissey RA, Hanson JA, et al. 2015. Anti-G-CSF treatment induces protective tumor immunity in mouse colon cancer by promoting NK cell, macrophage and T cell responses. Oncotarget 6: 22338-22347. https://doi.org/10.18632/oncotarget.4169
  27. Meng CY, Yin XW, Liu JT, Tang KF, Tang HC, Liao JH. 2018. TIMP-1 is a novel serum biomarker for the diagnosis of colorectal cancer: a meta- analysis. PLoS One 13: e0207039.
  28. Sanjabi S, Zenewicz LA, Kamanaka M, Flavell RA. 2009. Anti-inflammatory and pro-inflammatory roles of TGF-β, IL-10, and IL-22 in immunity and autoimmunity. Curr. Opin. Pharmacol. 9: 447-453. https://doi.org/10.1016/j.coph.2009.04.008
  29. Li G, Ren J, Hu Q, Deng Y, Chen G, Guo K, et al. 2016. Oral pirfenidone protects against fibrosis by inhibiting fibroblast proliferation and TGF-beta signaling in a murine colitis model. Biochem. Pharmacol. 117: 57-67. https://doi.org/10.1016/j.bcp.2016.08.002
  30. Hahm KB, Im YH, Parks TW, Park SH, Markowitz S, Jung HY, et al. 2001. Loss of transforming growth factor beta signalling in the intestine contributes to tissue injury in inflammatory bowel disease. Gut 49: 190-198. https://doi.org/10.1136/gut.49.2.190
  31. McFarland LV. 2010. Systematic review and meta-analysis of Saccharomyces boulardii in adult patients. World J. Gastroenterol. 16: 2202-2222. https://doi.org/10.3748/wjg.v16.i18.2202